13 research outputs found
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Understanding vaccine-elicited protection against SARS-CoV-2 variants and other sarbecoviruses is
key for guiding public health policies. We show that a clinical stage multivalent SARS-CoV-2 spike
receptor-binding domain nanoparticle vaccine (RBD-NP) protects mice from SARS-CoV-2 challenge
after a single immunization, indicating a potential dose-sparing strategy. We benchmarked serum
neutralizing activity elicited by RBD-NP in non-human primates against a lead prefusion-stabilized
SARS-CoV-2 spike (HexaPro) using a panel of circulating mutants. Polyclonal antibodies elicited by
both vaccines are similarly resilient to many RBD residue substitutions tested although mutations at
and surrounding position 484 have negative consequences for neutralization. Mosaic and cocktail
nanoparticle immunogens displaying multiple sarbecovirus RBDs elicit broad neutralizing activity in
mice and protect mice against SARS-CoV challenge even in the absence of SARS-CoV RBD in the
vaccine. This study provides proof of principle that multivalent sarbecovirus RBD-NPs induce
heterotypic protection and motivates advancing such broadly protective sarbecovirus vaccines to the
clinic
Recommended from our members
Social Determinants of Health Curriculum for Fourth-Year Medical Students Rotating in an Urban, Safety-Net Emergency Department
South Asian Stories: Elements of Culture and Faith
Children of the South Asian diaspora come from a vast variety of social, cultural, and religious backgrounds. Join author and New York Times\u27 Wirecutter journalist Kaitlyn Wells as she chats with three picture book authors of South Asian heritage about their experiences sharing aspects of culture and faith in the midst of storytelling. This session features members of KidLit in Color
Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009
Enteric fever is responsible for significant morbidity in South Asia and high prevalence of severe disease is seen in children under two years of age. Effective typhoid vaccines are available, but they cannot be used for children under two years of age and also have some limitations in older age groups. Participants supported development of a Salmonella Typhi conjugate vaccine able to induce effective, long-lasting immunity in young children. The role of Salmonella Paratyphi A as a cause of enteric fever was discussed and consensus reached that a bivalent S. Typhi-S. Paratyphi A conjugate vaccine is highly desirable; however, considering disease epidemiology and the advanced status of vaccine development, rapid introduction of monovalent S. Typhi conjugate vaccine into vaccination programs of South Asia was recommended. Prevention should be emphasized, available vaccines used, and efforts toward improving sanitation continued.
Success of the new vaccine will depend on several factors, including delivery costs and governmental ability to adopt and implement suitable immunization programs. To ensure good immunization coverage, the conjugate vaccine could be administered either to young infants, concomitantly with infant EPI vaccines, or to older infants, concomitantly with measles vaccine, currently given at 9 to 12 months. The need for new combination vaccines, containing both EPI and typhoid antigens, was discussed as a tool to increase coverage and reduce the number of injections and priority conflicts in a crowded infant vaccination schedule. However, stand-alone enteric fever conjugate vaccines would allow more flexibility to immunize different age groups and therefore should be rapidly developed